Description

Drug Classification:

Montelukast belongs to a class of drugs known as leukotriene receptor antagonists. It selectively inhibits the action of leukotriene D4 at the cysteinyl leukotriene receptor, thereby reducing bronchoconstriction and inflammation associated with asthma and allergic rhinitis.

Formulations:

• Montelukast Tablets:
  • Strength: Available in 5mg and 10mg tablets.
  • Product Form: Oral tablets for convenient administration.
  • Packing Specifications: Packaged in blister packs containing 14 tablets each.

Indications:

Montelukast Tablets are indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients aged 12 months and older. They are also indicated for the relief of symptoms of allergic rhinitis, including nasal congestion, sneezing, itching, and rhinorrhea.

Usage:

• Montelukast Tablets should be taken orally with or without food, as directed by a healthcare professional.
• For asthma prophylaxis, the medication is typically taken once daily in the evening.
• For allergic rhinitis, Montelukast Tablets can be taken once daily, regardless of meal timing.
• It is essential to adhere to the prescribed dosage and follow the instructions provided by a healthcare provider.

Dosage:

• For asthma prophylaxis:
  • Adults and adolescents (aged 15 years and older): 10mg once daily.
  • Pediatric patients (aged 12 months to 14 years):
    • 10mg once daily for those weighing more than 25kg.
    • 5mg once daily for those weighing 6 to 25kg.
• For allergic rhinitis:
  • Adults and adolescents (aged 15 years and older): 10mg once daily.
  • Pediatric patients (aged 6 to 14 years): 5mg once daily.
  • Pediatric patients (aged 2 to 5 years): 4 mg once daily.

Pharmacokinetics:

• Montelukast is well absorbed from the gastrointestinal tract, with peak plasma concentrations achieved within 3 to 4 hours following oral administration.
• The drug is extensively metabolized in the liver via cytochrome P450 enzymes, primarily CYP2C8 and CYP3A4.
• Montelukast and its metabolites are primarily excreted in the feces, with a terminal elimination half-life of approximately 2.7 to 5.5 hours.

Pharmacodynamics:

• Montelukast exerts its pharmacological effects by selectively antagonizing the leukotriene D4 receptor. By blocking the action of leukotriene D4, Montelukast reduces bronchoconstriction, airway inflammation, mucous secretion, and edema associated with asthma and allergic rhinitis.

Side Effects:

• Common side effects of Montelukast Tablets may include headache, abdominal pain, diarrhea, nausea, and fatigue.
• Rare but serious side effects may include neuropsychiatric events such as agitation, aggression, hallucinations, depression, and suicidal thoughts.
• Patients should be monitored for any adverse reactions during treatment with Montelukast, and healthcare providers should be informed of any concerning symptoms.

Experience the relief provided by AIT Pharmaceuticals Division’s Montelukast Tablets for asthma and allergic rhinitis management. For more information, please contact us. We are committed to providing effective pharmaceutical solutions to healthcare professionals worldwide.